Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.-MedSci.cn

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

Plimack, ER; Rini, BI; Stus, V; Gafanov, R; Waddell, T; Nosov, D; Pouliot, F; Soulieres, D; Melichar, B; Vynnychenko, I; Azevedo, SJ; Borchiellini, D; McDermott, RS; Bedke, J; Tamada, S; Yin, LN; Chen, M; Molife, LR; Atkins, MB; Powles, T

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务